Full Press Release Details
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181%
Asset Expansion in Q3 2025
Silicon Valley, CA (November 03, 2025) - ABVC BioPharma, Inc..
(NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology,
and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update
on recent corporate developments.
Valuations provided above are based on third-party valuation.
Financial Highlights
Operational Highlights
The Company continues to follow an asset-light business model focused
on licensing, partnerships, and collaborative development. Recent investments in physical assets in Taiwan are expected to enhance future
research and manufacturing capacity. ABVC seeks to advance its key pipeline assets and to explore additional partnerships that support
its long-term growth strategy.
"Our third-quarter results reflect continued progress in both
our licensing revenue and asset development activities," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "We remain focused
on executing our strategic priorities to create sustainable value for our shareholders over the long term."
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus ) under development. For its drug
products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University
of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus , the Company intends to conduct pivotal clinical trials
(Phase III) through global partnerships.
Forward-Looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based
on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control,
and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size
and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval
to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are
urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer
to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United
States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of
the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such state or jurisdiction.
Email: uttam@ambrivis.com